Explore

Reuters Reuters
Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results

Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results

By Michael Erman July 30 (Reuters) - Bristol Myers Squibb raised its full-year revenue and profit forecast on Thursday after reporting second-quarter results that came in well ahead of Wall Street estimates, driven by strong sales of blood thinner Eliquis and newer drugs like heart medicine Camzyos
Reuters Reuters
Regeneron beats quarterly estimates on eczema drug strength, shares rise

Regeneron beats quarterly estimates on eczema drug strength, shares rise

July 30 (Reuters) - Regeneron on Thursday beat Wall Street estimates for second-quarter revenue and profit, helped by strong demand for its eczema drug Dupixent and a high-dose version of its eye drug Eylea. Shares rose nearly 5% before the bell.
Trendline Trendline
Universal Health Services Exceeds Q2 Expectations, Adjusts Full-Year Earnings Forecast

Universal Health Services Exceeds Q2 Expectations, Adjusts Full-Year Earnings Forecast

Universal Health Services Exceeds Q2 Expectations, Adjusts Full-Year Earnings Forecast
Trendline Trendline
Cigna Reports 7% Increase in Q2 Revenue, Adjusts 2026 Outlook

Cigna Reports 7% Increase in Q2 Revenue, Adjusts 2026 Outlook

Cigna Reports 7% Increase in Q2 Revenue, Adjusts 2026 Outlook
Trendline Trendline
Humana Reports Strong Q2 Earnings with Revenue Surpassing $40 Billion

Humana Reports Strong Q2 Earnings with Revenue Surpassing $40 Billion

Humana Reports Strong Q2 Earnings with Revenue Surpassing $40 Billion
Trendline Trendline
Incyte Reports 38% Revenue Increase in Q2 2026, Updates Financial Guidance

Incyte Reports 38% Revenue Increase in Q2 2026, Updates Financial Guidance

Incyte Reports 38% Revenue Increase in Q2 2026, Updates Financial Guidance
Trendline Trendline
Pfizer and Eli Lilly: Divergent Investment Strategies in the Pharmaceutical Sector

Pfizer and Eli Lilly: Divergent Investment Strategies in the Pharmaceutical Sector

Pfizer and Eli Lilly: Divergent Investment Strategies in the Pharmaceutical Sector
Trendline Trendline
Alkermes Reports Break-Even Q2 Earnings, Revenue Surpasses Estimates

Alkermes Reports Break-Even Q2 Earnings, Revenue Surpasses Estimates

Alkermes Reports Break-Even Q2 Earnings, Revenue Surpasses Estimates
Trendline Trendline
Centene Corporation Reports $1.1 Billion Q2 Profit, Surpassing Expectations

Centene Corporation Reports $1.1 Billion Q2 Profit, Surpassing Expectations

Centene Corporation Reports $1.1 Billion Q2 Profit, Surpassing Expectations
Trendline Trendline
Alkermes Reports Break-Even Q2 Earnings, Revenue Surpasses Expectations

Alkermes Reports Break-Even Q2 Earnings, Revenue Surpasses Expectations

Alkermes Reports Break-Even Q2 Earnings, Revenue Surpasses Expectations
Trendline Trendline
MapLight's Schizophrenia Drug Fails to Surpass Cobenfy in Phase 2 Trial, Leading to Stock Decline

MapLight's Schizophrenia Drug Fails to Surpass Cobenfy in Phase 2 Trial, Leading to Stock Decline

MapLight's Schizophrenia Drug Fails to Surpass Cobenfy in Phase 2 Trial, Leading to Stock Decline
Trendline Trendline
Centene Corporation Reports $1.1 Billion Q2 Profit, Raises 2026 Guidance

Centene Corporation Reports $1.1 Billion Q2 Profit, Raises 2026 Guidance

Centene Corporation Reports $1.1 Billion Q2 Profit, Raises 2026 Guidance